Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/210403
Title: | Psychotropic drug repurposing for COVID-19: A Systematic Review and Meta-Analysis |
Author: | Gómez Ramiro, Marta Vieta i Pascual, Eduard, 1963- Fico, Giovanna Isayeva, Ulker De Prisco, Michele Oliva, Vincenzo Solé, Brisa Montejo, Laura Grande i Fullana, Iria Arbelo, Néstor Pintor Pérez, Luís Carpiniello, Bernardo Manchia, Mirko Murru, Andrea 2EPs Group |
Keywords: | Psicofàrmacs Metaanàlisi Ressenyes sistemàtiques (Investigació mèdica) COVID-19 Antidepressius Antipsicòtics Psychotropic drugs Meta-analysis Systematic reviews (Medical research) COVID-19 Antidepressants Antipsychotic drugs |
Issue Date: | 20-Oct-2022 |
Publisher: | Elsevier B.V. |
Abstract: | Several psychotropic drugs, including antidepressants (AD), mood stabilizers, and antipsychotics (AP) have been suggested to have favorable effects in the treatment of COVID-19. The aim of this systematic review and meta-analysis was to collect evidence from studies concerning the scientific evidence for the repurposing of psychotropic drugs in COVID-19 treatment. Two independent authors searched PubMed-MEDLINE, Scopus, PsycINFO, and ClinicalTrials.gov databases, and reviewed the reference lists of articles for eligible articles published up to 13th December, 2021. All computational, preclinical and clinical (observational and/or RCTs) studies on the effect of any psychotropic drug on Sars-CoV-2 or patients with COVID-19 were considered for inclusion. We conducted random effect meta-analyses on clinical studies reporting the effect of AD or AP on COVID-19 outcomes. 29 studies were included in the synthesis: 15 clinical, 9 preclinical, and 5 computational studies. 9 clinical studies could be included in the quantitative analyses. AD did not increase the risk of severe COVID-19 (RR= 1.71; CI 0.65-4.51) or mortality (RR=0.94; CI 0.81-1.09). Fluvoxamine was associated with a reduced risk of mortality for COVID-19 (OR=0.15; CI 0.02-0.95). AP increased the risk of severe COVID-19 (RR=3.66; CI 2.76-4.85) and mortality (OR=1.53; CI 1.15-2.03). Fluvoxamine might be a possible candidate for psychotropic drug repurposing in COVID-19 due to its anti-inflammatory and antiviral potential, while evidence on other AD is still controversial. Although AP are associated with worse COVID-19 outcomes, their use should be evaluated case to case and ongoing treatment with antipsychotics should be not discontinued in psychiatric patients. |
Note: | Versió postprint del document publicat a: https://doi.org/10.1016/j.euroneuro.2022.10.004 |
It is part of: | European Neuropsychopharmacology, 2022, vol. 66, p. 30-44 |
URI: | http://hdl.handle.net/2445/210403 |
Related resource: | https://doi.org/10.1016/j.euroneuro.2022.10.004 |
ISSN: | 0924-977X |
Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
262346.pdf | 4.27 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License